Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
6.94 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 14.417 | 13.794 | 10.891 | 10.102 | 11.016 | 12.134 | 13.676 | 13.053 | 7.653 | 5.299 | 2.5 | 2.5 | 2.5 | 2.5 | 2.551 | 0.862 | 0.186 | 0.06 |
| Cost of Revenue
| 13.099 | 14.566 | 23.481 | 10.877 | 9.382 | 12.448 | 10.84 | 15.409 | 14.227 | 7.799 | 2.576 | 33.246 | 29.624 | 24.109 | 20.698 | 16.535 | 13.244 | 12.842 |
| Gross Profit
| 1.318 | -0.772 | -12.59 | -0.775 | 1.634 | -0.314 | 2.836 | -2.356 | -6.574 | -2.5 | -0.076 | -30.746 | -27.124 | -21.609 | -18.147 | -15.673 | -13.058 | -12.782 |
| Gross Profit Ratio
| 0.091 | -0.056 | -1.156 | -0.077 | 0.148 | -0.026 | 0.207 | -0.18 | -0.859 | -0.472 | -0.03 | -12.298 | -10.85 | -8.644 | -7.114 | -18.182 | -70.204 | -213.033 |
| Reseach & Development Expenses
| 70.028 | 64.16 | 66.082 | 70.007 | 55.06 | 46.677 | 43.98 | 40.836 | 38.439 | 32.441 | 48.291 | 33.246 | 29.624 | 24.109 | 20.698 | 16.535 | 13.244 | 12.842 |
| General & Administrative Expenses
| 31.833 | 31.408 | 30.458 | 29.199 | 28.29 | 22.874 | 19.838 | 19.488 | 21.199 | 21.074 | 19.202 | 15.69 | 13.854 | 8.937 | 7.574 | 6.964 | 5.159 | 5.561 |
| Selling & Marketing Expenses
| 0 | 0.108 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 31.833 | 31.408 | 30.458 | 29.199 | 28.29 | 22.874 | 19.838 | 19.488 | 21.199 | 21.074 | 19.202 | 15.69 | 13.854 | 8.937 | 7.574 | 6.964 | 5.159 | 5.561 |
| Other Expenses
| -0.392 | 0.16 | -2.624 | 1.581 | 4.989 | -0.103 | 3.49 | -0.107 | -0.021 | -0.034 | 0.027 | -0.029 | 0 | 0 | -0.14 | 0 | 0 | 0 |
| Operating Expenses
| 101.861 | 95.568 | 96.54 | 98.775 | 83.349 | 69.551 | 63.818 | 60.217 | 59.617 | 53.481 | 67.46 | 48.902 | 43.429 | 32.984 | 28.132 | 23.336 | 18.217 | 18.343 |
| Operating Income
| -100.543 | -96.34 | -109.13 | -99.55 | -81.715 | -69.865 | -60.982 | -62.573 | -66.191 | -55.981 | -64.96 | -46.402 | -40.929 | -30.484 | -25.581 | -22.474 | -18.217 | -18.343 |
| Operating Income Ratio
| -6.974 | -6.984 | -10.02 | -9.854 | -7.418 | -5.758 | -4.459 | -4.794 | -8.649 | -10.564 | -25.984 | -18.561 | -16.372 | -12.194 | -10.028 | -26.072 | -97.941 | -305.717 |
| Total Other Income Expenses Net
| 2.48 | 4.188 | 14.506 | 1.581 | 4.989 | 4.538 | 3.49 | 2.128 | 0.631 | 0.002 | 0.027 | -0.856 | -2.472 | -0.233 | -0.185 | -1.044 | -0.324 | -0.081 |
| Income Before Tax
| -98.063 | -92.152 | -94.624 | -93.017 | -76.726 | -65.327 | -57.492 | -60.445 | -65.56 | -55.979 | -64.933 | -47.428 | -43.401 | -30.717 | -25.766 | -23.873 | -18.943 | -18.424 |
| Income Before Tax Ratio
| -6.802 | -6.681 | -8.688 | -9.208 | -6.965 | -5.384 | -4.204 | -4.631 | -8.567 | -10.564 | -25.973 | -18.971 | -17.36 | -12.287 | -10.1 | -27.695 | -101.844 | -307.067 |
| Income Tax Expense
| -0.523 | -0.779 | -1.628 | 1.606 | -5.543 | -4.538 | -0.013 | -2.128 | -0.014 | -0.002 | 0.019 | 1.026 | 2.472 | 0.233 | -0.484 | 1.399 | 0.726 | 0.081 |
| Net Income
| -97.54 | -91.373 | -92.996 | -93.017 | -76.726 | -60.789 | -57.479 | -58.317 | -65.546 | -55.977 | -64.933 | -47.428 | -43.401 | -30.717 | -25.766 | -23.873 | -18.943 | -18.424 |
| Net Income Ratio
| -6.766 | -6.624 | -8.539 | -9.208 | -6.965 | -5.01 | -4.203 | -4.468 | -8.565 | -10.564 | -25.973 | -18.971 | -17.36 | -12.287 | -10.1 | -27.695 | -101.844 | -307.067 |
| EPS
| -0.4 | -0.39 | -0.4 | -0.43 | -0.38 | -0.32 | -0.31 | -0.34 | -0.38 | -0.33 | -0.38 | -0.28 | -0.31 | -0.2 | -0.17 | -0.21 | -0.17 | -0.16 |
| EPS Diluted
| -0.4 | -0.39 | -0.4 | -0.43 | -0.38 | -0.32 | -0.31 | -0.34 | -0.38 | -0.33 | -0.38 | -0.28 | -0.31 | -0.2 | -0.17 | -0.21 | -0.17 | -0.16 |
| EBITDA
| -92.543 | -88.94 | -93.514 | -85.414 | -81.715 | -61.58 | -60.982 | -57.443 | -62.76 | -53.198 | -64.96 | -43.945 | -38.569 | -29.066 | -24.395 | -21.571 | -17.169 | -17.186 |
| EBITDA Ratio
| -6.419 | -6.448 | -8.586 | -8.455 | -7.418 | -5.075 | -4.459 | -4.401 | -8.201 | -10.039 | -25.984 | -17.578 | -15.428 | -11.626 | -9.563 | -25.024 | -92.306 | -286.433 |